Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication June 13, 2023
- Revision received August 18, 2023
- Published online November 2, 2023.
Article Versions
- previous version (September 28, 2023 - 08:44).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Oliver Sartor1,2,
- Elisa Ledet1,
- Minqui Huang1,
- Jennifer Schwartz1,
- Alex Lieberman1,
- Brian Lewis1,
- Jodi Layton1,
- Pedro Barata1,
- Albert Jang1,
- Madeline Hawkins1,
- Olivia Pocha1,
- Sree Lanka1 and
- Kendra Harris1,3
- 1Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana;
- 2Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota; and
- 3Department of Radiation Oncology, Orlando Health, Orlando, Florida
- For correspondence or reprints, contact Oliver Sartor (sartor.oliver{at}mayo.edu)
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer
- The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy
- Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice
- Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction